{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T09:53:55Z","timestamp":1770976435483,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2014,4,11]],"date-time":"2014-04-11T00:00:00Z","timestamp":1397174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2014,9]]},"abstract":"\n Aim<\/jats:title>\n \n Glucagon\u2010like peptide\u20101 (\n GLP<\/jats:styled-content>\n \u20101) receptor agonists improve islet function and delay gastric emptying in patients with type 2 diabetes mellitus (\n T2DM<\/jats:styled-content>\n ). This meta\u2010analysis aimed to investigate the effects of the once\u2010daily prandial\n GLP<\/jats:styled-content>\n \u20101 receptor agonist lixisenatide on postprandial plasma glucose (\n PPG<\/jats:styled-content>\n ), glucagon and insulin levels.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Six randomized, placebo\u2010controlled studies of lixisenatide 20\u2009\u00b5g once daily were included in this analysis: lixisenatide as monotherapy (\n GetGoal<\/jats:styled-content>\n \u2010Mono), as add\u2010on to oral antidiabetic drugs (\n OADs<\/jats:styled-content>\n ;\n GetGoal<\/jats:styled-content>\n \u2010M,\n GetGoal<\/jats:styled-content>\n \u2010S) or in combination with basal insulin (\n GetGoal<\/jats:styled-content>\n \u2010L,\n GetGoal<\/jats:styled-content>\n \u2010Duo\u20101 and\n GetGoal<\/jats:styled-content>\n \u2010L\u2010Asia). Change in 2\u2010h\n PPG<\/jats:styled-content>\n and glucose excursion were evaluated across six studies. Change in 2\u2010h glucagon and postprandial insulin were evaluated across two studies. A meta\u2010analysis was performed on least square (\n LS<\/jats:styled-content>\n ) mean estimates obtained from analysis of covariance (\n ANCOVA<\/jats:styled-content>\n )\u2010based linear regression.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Lixisenatide significantly reduced 2\u2010h\n PPG<\/jats:styled-content>\n from baseline (\n LS<\/jats:styled-content>\n mean difference vs. placebo: \u22124.9\u2009mmol\/l, p\u2009<\u20090.001) and glucose excursion (\n LS<\/jats:styled-content>\n mean difference vs. placebo: \u22124.5\u2009mmol\/l, p\u2009<\u20090.001). As measured in two studies, lixisenatide also reduced postprandial glucagon (\n LS<\/jats:styled-content>\n mean difference vs. placebo: \u221219.0\u2009ng\/l, p\u2009<\u20090.001) and insulin (\n LS<\/jats:styled-content>\n mean difference vs. placebo: \u221264.8 pmol\/l, p\u2009<\u20090.001). There was a stronger correlation between 2\u2010h postprandial glucagon and 2\u2010h\n PPG<\/jats:styled-content>\n with lixisenatide than with placebo.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Lixisenatide significantly reduced 2\u2010h\n PPG<\/jats:styled-content>\n and glucose excursion together with a marked reduction in postprandial glucagon and insulin; thus, lixisenatide appears to have biological effects on blood glucose that are independent of increased insulin secretion. These effects may be, in part, attributed to reduced glucagon secretion.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12290","type":"journal-article","created":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T10:58:41Z","timestamp":1395140321000},"page":"861-868","source":"Crossref","is-referenced-by-count":25,"title":["Pronounced reduction of postprandial glucagon by lixisenatide: a meta\u2010analysis of randomized clinical trials"],"prefix":"10.1111","volume":"16","author":[{"given":"B.","family":"Ahr\u00e9n","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences Lund University Lund Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.\u2010F.","family":"Gautier","sequence":"additional","affiliation":[{"name":"Centre of Diabetes and its Complications Lariboisi\u00e8re Hospital Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Berria","sequence":"additional","affiliation":[{"name":"Global Medical Affairs Sanofi Bridgewater NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Stager","sequence":"additional","affiliation":[{"name":"Global Medical Affairs Sanofi Bridgewater NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Aronson","sequence":"additional","affiliation":[{"name":"LMC Diabetes and Endocrinology Toronto Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. J.","family":"Bailey","sequence":"additional","affiliation":[{"name":"School of Life and Health Sciences, Aston University Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,4,11]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.37.6.667"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197007162830301"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.86.8.7750"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197108192850806"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(98)90185-8"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.55.04.06.db05-1449"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.11.4053"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2011.01.010"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.2.473"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01560.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-005-1878-0"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.1997.273.5.E981"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.2337\/db09-1414"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12076"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/db10-0474"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1935"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2006"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12121"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2709"},{"key":"e_1_2_8_22_1","first-page":"1","article-title":"Efficacy and safety of lixisenatide once daily versus placebo in patients with T2DM insufficiently controlled on sulfonylurea\u2009+\u2009metformin (GetGoal\u2010S)","volume":"54","author":"Ratner R","year":"2011","journal-title":"Diabetologia"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2454"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2462"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01618.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)92375-2"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2006.01.004"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/279530"},{"key":"e_1_2_8_29_1","first-page":"283","article-title":"Impact of lack of suppression of glucagon on glucose tolerance in humans","volume":"277","author":"Shah P","year":"1999","journal-title":"Am J Physiol"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2013.04.001"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01449.x"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108596"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1210\/me.2010-0120"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050954"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108649"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.115717"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.2337\/db06-0222"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.2337\/diab.46.5.785"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00035.2013"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.10.3434"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(91)80182-3"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12290","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:48:15Z","timestamp":1761864495000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,11]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1111\/dom.12290"],"URL":"https:\/\/doi.org\/10.1111\/dom.12290","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,11]]}}}